ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 2115 • ACR Convergence 2024

    Clinical Impact of Acute Symptomatic Vertebral Fractures in the United States: An Observational Study

    Neil Binkley1, Michele McDermott2, Eric Yeh2, Joseph Lane3, Jolenta Cheung4, Mona Amet4 and Felicia Cosman5, 1University of Wisconsin, Madison, 2Amgen Inc., Thousand Oaks, 3Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 4Adelphi Real World, Bollington, United Kingdom, 5Columbia University, College of Physicians and Surgeons, New York, NY

    Background/Purpose: To characterize pain status (frequency, severity, persistency) and effect on activities of daily living (ADLs) in patients with symptomatic vertebral fractures (VF).Methods: This was…
  • Abstract Number: 2138 • ACR Convergence 2024

    DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis

    Edgar Wiebe1, Elisa Schilling2, Dörte Huscher2, Zhivana Boydzhieva3, andriko Palmowski4, Sandra Hermann5, burkhard Muche5, Gerhard Krönke5 and FRANK HARTMUT DR. BUTTGEREIT1, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité-Universitätsmedizin Berlin, Berlin, Germany, 3Charité Universittsmedizin, Berlin, Germany, 4Charité - Universittsmedizin Berlin, Berlin, Germany, 5Rheumatology, Charité, Berlin, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis and fragility fracture risk that may not be reflected by areal bone mineral density (aBMD) measurements alone.…
  • Abstract Number: 2679 • ACR Convergence 2024

    Predictors of Fracture in SLE: A Longitudinal Cohort Study

    Kristen Chao1, Andrea Fava2, Daniel Goldman3, Laurence Magder4 and Michelle Petri3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Timonium, MD, 4University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Fractures are one of the most common damage items in the SLICC/ACR Damage Index. Although commonly attributed to corticosteroid use, the complexity of ways…
  • Abstract Number: 1022 • ACR Convergence 2024

    Social Determinants of Health in Osteoporosis Treatment Patterns Among Adults with Rheumatoid Arthritis and Major Osteoporotic Fracture in the All of Us Research Program: A Cross-Sectional Study

    Marshall Weber1, Brinda Basida2, Colton Hoffer2 and Rachel Elam3, 1Augusta University, Augusta, GA, 2Augusta University / VA Augusta Health System, Augusta, GA, 3Augusta University, Evans, GA

    Background/Purpose: Despite widely available bone health pharmacologic therapies, there is a significant osteoporosis treatment gap in individuals with rheumatoid arthritis (RA). The aim of this…
  • Abstract Number: 2117 • ACR Convergence 2024

    The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260

    Camille Ghio, Robinson Gravier-Dumonceau, Pierre Lafforgue, Roch Giorgi and Thao Pham, Assistance Publique-Hôpitaux de Marseille, Marseille, France

    Background/Purpose: Although antiresorptive treatments, including bisphosphonates and denosumab, have demonstrated their efficacy in treating osteoporosis. However, osteonecrosis of the jaw has been reported as a…
  • Abstract Number: 2139 • ACR Convergence 2024

    Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro

    Johannes Plank1, Moritz Pfeiffenberger1, Alexandra Damerau1, Timo Gaber1 and FRANK HARTMUT DR. BUTTGEREIT2, 1Charité-Universitätsmedizin Berlin, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Berlin, Germany, 2Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, often leading to pain, fractures and reduced mobility in…
  • Abstract Number: PP10 • ACR Convergence 2024

    Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally

    Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY

    Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
  • Abstract Number: 2005 • ACR Convergence 2023

    Secondary Prevention of Osteoporosis in Hip Fracture Care for Elderly Patients. Clinical and Functional Profile of Users

    Belén Miguel Ibáñez, Alfonso González Ramírez, Olga Martínez González, Ana Isabel Turrión Nieves, Marta Ibáñez Martínez, Carolina Cristina Chacón Vélez, Laura Blanco Ramis, Manuel Cipriano Martín Martínez, Cristina Hidalgo Calleja, Carlos Alberto Montilla Morales, Susana Gómez Castro, Juan Francisco Blanco Blanco and Carmen Pablos Hernández, University Healthcare Complex of Salamanca, Salamanca, Spain

    Background/Purpose: Osteoporosis is a first-rate problem in an increasingly ageing population. Falls among the elderly are a severe geriatric syndrome with relevant secondary effects. Fractures…
  • Abstract Number: 2429 • ACR Convergence 2023

    Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial

    Chi Chiu Mok1, SAU MEI TSE2, Kar Li Kelly Chan3 and Wai Han Ma1, 1Tuen Mun Hospital, Hong Kong, Hong Kong, 2Tuen Mun Hospital, Hong Kong, China, 3Tuen Mun Hospital, Shatin, China

    Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients treated with glucocorticoids (GCs). Methods: Adult patients (≥18 years)…
  • Abstract Number: 2006 • ACR Convergence 2023

    Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic

    Massiel Jimenez Artiles1, Roshan Subedi2, Qi Wang3, Bishara Jahshan4, Khalid Gadir4 and Waleed Quwatli5, 1Unity Hospital, Rochester Regional Health, Greece, NY, 2Rochester Regional Health/Unity Hospital, Greece, NY, 3Rochester Regional Health/Unity Hospital, Rochester, NY, 4Unity Hospital, Rochester Regional Health, Rochester, NY, 5Unity Hospital/ Rochester Regional Health, Rochester, NM

    Background/Purpose: Osteoporotic fractures, especially hip fractures, are associated with significant morbidity, including limitations in ambulation, disability, and decreased quality of life. The aim of this…
  • Abstract Number: 2527 • ACR Convergence 2023

    Risk Factors for Bone Loss in Systemic Lupus Erythematosus

    Nima Madanchi1, Andrea Fava2, Daniel Goldman3, Larry Magder4 and Michelle Petri3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 4University of Maryland, Baltimore, MD

    Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…
  • Abstract Number: 1072 • ACR Convergence 2023

    Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors

    Maria Suarez-Almazor1, Carrie Ye2, Bo Zhao3, Juan Ruiz3, Hui Zhao3, Noha Abdel-Wahab4 and William Leslie5, 1MD Anderson Cancer Center, Houston, TX, 2University of Alberta, Edmonton, AB, Canada, 3The University of Texas, MD Anderson Cancer Center, Houston, TX, 4University of Texas MD Anderson Cancer Center, Houston, TX, 5University of Manitoba, Internal Medicine, Winnipeg, MB, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. Despite their efficacy on tumor outcomes they can cause severe and sometimes long-standing immune-related…
  • Abstract Number: 2007 • ACR Convergence 2023

    Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study

    Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY

    Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
  • Abstract Number: 2528 • ACR Convergence 2023

    Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States

    Min Kim1, Vanessa C. Brunetti1, Felicia Cosman2, Jeffrey Curtis3, E Michael Lewiecki4, Matthew Phelan5, Peter Samai5, Michele McDermott1, Tzu-Chieh Lin1, M Alan Brookhart6 and Kathleen Hurwitz5, 1Amgen, Inc., Thousand Oaks, CA, 2Columbia University, New York, NY, 3University of Alabama at Birmingham, Birmingham, AL, 4New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 5Target RWE, Durham, NC, 6Department of Population Health Sciences, Duke University, Durham, NC

    Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…
  • Abstract Number: 1098 • ACR Convergence 2023

    Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

    Kelly Tran1, Ellen Ann Sockman1, Rachel Salyer1, Megan Young1, Aisha Abbasi1 and Devanshu Verma2, 1West Virginia University Hospital, Morgantown, WV, 2West Virginia University, Morgantown, WV

    Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology